There are several trials that completed enrollment that we haven't heard survival data for. Gem panc (completed enrollment 15 months ago), NSCLC, (enrollment 12 months ago, already has an OS that is about 60% better than the standard of care) SCLC, (completed enrollment about 10 months ago). SCLC is an interesting one because the company has said REO works well on SC, but we haven't heard anything about the survival data. Although SC is typically included in NSCLC trials, the data isn't broken out. Like Kras, SC is a subset that does not respond well (or at all) to current therapies. This could be interesting.
nome - This "ongoing" trial is open label. Survivors would have to still be alive after anywhere between 15 and 50 months. Way, way beyond the 6-8 mo life expectancy for these patients. If the OS results are that stunning (+120% -700%) why would ONC not release them? How much difference would another 2/3 monthsmake? I assume if the results were poor they would have been obligated to make that public. Does this suggest the trial results are marginal?